Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
Abstract Background Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms’ tumor 1 and mucin 1 vaccin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13256-024-04363-z |
| _version_ | 1827327298964029440 |
|---|---|
| author | Takuya Kosumi Masanori Kobayashi Shigetaka Shimodaira Haruo Sugiyama Shigeo Koido |
| author_facet | Takuya Kosumi Masanori Kobayashi Shigetaka Shimodaira Haruo Sugiyama Shigeo Koido |
| author_sort | Takuya Kosumi |
| collection | DOAJ |
| description | Abstract Background Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms’ tumor 1 and mucin 1 vaccine in combination with erlotinib, a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, for more than 699 days without recurrence or metastasis. Case presentation A 63-year-old Korean woman was diagnosed with lung adenocarcinoma by pathology and computed tomography. The adenocarcinoma showed an epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase expression, and less than 1% expression of programmed death ligand 1. She received erlotinib alone for approximately 1 month. She then received erlotinib and the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine. The diameter of the erythema at the vaccinated sites was 30 mm at 48 hours after the first vaccination. Moreover, it was maintained at more than 20 mm during the periods of vaccination. These results suggested the induction of antitumor immunity by the vaccine. Remarkably, the tumor size decreased significantly to 12 mm, a 65.7% reduction, after combined therapy with eight doses of the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine and erlotinib for 237 days based on fluorodeoxyglucose uptake by positron emission tomography/computed tomography and computed tomography. Interestingly, after 321 days of combination therapy, the clinical findings improved, and no tumor was detected based on computed tomography. Validation of the tumor’s disappearance persisted for at least 587 days after treatment initiation, without any indication of recurrence or metastasis. Conclusion Standard anticancer therapy combined with the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine may have therapeutic effects for such patients with unresectable lung adenocarcinoma. |
| first_indexed | 2024-03-07T14:59:12Z |
| format | Article |
| id | doaj.art-2a11a13b50cf4c7b849b3e9409165fe7 |
| institution | Directory Open Access Journal |
| issn | 1752-1947 |
| language | English |
| last_indexed | 2024-03-07T14:59:12Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Medical Case Reports |
| spelling | doaj.art-2a11a13b50cf4c7b849b3e9409165fe72024-03-05T19:14:54ZengBMCJournal of Medical Case Reports1752-19472024-02-011811610.1186/s13256-024-04363-zDendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case reportTakuya Kosumi0Masanori Kobayashi1Shigetaka Shimodaira2Haruo Sugiyama3Shigeo Koido4Kyushukouseikai ClinicOkazakiyuuai ClinicDepartment of Regenerative Medicine, Kanazawa Medical UniversityDepartment of Cancer Immunology, Osaka University Graduate School of MedicineDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kashiwa Hospital, The Jikei University School of MedicineAbstract Background Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms’ tumor 1 and mucin 1 vaccine in combination with erlotinib, a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, for more than 699 days without recurrence or metastasis. Case presentation A 63-year-old Korean woman was diagnosed with lung adenocarcinoma by pathology and computed tomography. The adenocarcinoma showed an epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase expression, and less than 1% expression of programmed death ligand 1. She received erlotinib alone for approximately 1 month. She then received erlotinib and the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine. The diameter of the erythema at the vaccinated sites was 30 mm at 48 hours after the first vaccination. Moreover, it was maintained at more than 20 mm during the periods of vaccination. These results suggested the induction of antitumor immunity by the vaccine. Remarkably, the tumor size decreased significantly to 12 mm, a 65.7% reduction, after combined therapy with eight doses of the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine and erlotinib for 237 days based on fluorodeoxyglucose uptake by positron emission tomography/computed tomography and computed tomography. Interestingly, after 321 days of combination therapy, the clinical findings improved, and no tumor was detected based on computed tomography. Validation of the tumor’s disappearance persisted for at least 587 days after treatment initiation, without any indication of recurrence or metastasis. Conclusion Standard anticancer therapy combined with the dendritic cells pulsed with Wilms’ tumor 1 and mucin 1 vaccine may have therapeutic effects for such patients with unresectable lung adenocarcinoma.https://doi.org/10.1186/s13256-024-04363-zCancer vaccinesDendritic cellsWT1MUC1Lung cancer |
| spellingShingle | Takuya Kosumi Masanori Kobayashi Shigetaka Shimodaira Haruo Sugiyama Shigeo Koido Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report Journal of Medical Case Reports Cancer vaccines Dendritic cells WT1 MUC1 Lung cancer |
| title | Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report |
| title_full | Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report |
| title_fullStr | Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report |
| title_full_unstemmed | Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report |
| title_short | Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report |
| title_sort | dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma a case report |
| topic | Cancer vaccines Dendritic cells WT1 MUC1 Lung cancer |
| url | https://doi.org/10.1186/s13256-024-04363-z |
| work_keys_str_mv | AT takuyakosumi dendriticcellvaccinationincombinationwitherlotinibinapatientwithinoperablelungadenocarcinomaacasereport AT masanorikobayashi dendriticcellvaccinationincombinationwitherlotinibinapatientwithinoperablelungadenocarcinomaacasereport AT shigetakashimodaira dendriticcellvaccinationincombinationwitherlotinibinapatientwithinoperablelungadenocarcinomaacasereport AT haruosugiyama dendriticcellvaccinationincombinationwitherlotinibinapatientwithinoperablelungadenocarcinomaacasereport AT shigeokoido dendriticcellvaccinationincombinationwitherlotinibinapatientwithinoperablelungadenocarcinomaacasereport |